Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Merck's experimental injectable remigromig held its own against the current standard treatment for diabetic macular edema (DME) in a 52-week trial. The drug works via a novel Wnt pathway mechanism — potentially the first new retinal vascular treatment approach in over 20 years. However, higher rates of discontinuation due to retinal vascular complications have analysts calling for more safety data before drawing firm conclusions.
Merck's experimental drug remigromig matched the performance of Roche's ranibizumab — the current gold standard — in improving visual acuity in patients with diabetic macular edema (DME) over 52 weeks. The 984-patient trial showed non-inferiority on the primary endpoint of best-corrected visual acuity (BCVA) change from baseline, a meaningful result for a drug that works through an entirely different mechanism than existing therapies.
Unlike anti-VEGF agents that block blood vessel growth, remigromig activates the Wnt pathway to repair the retina's leaky blood-vessel barrier and reduce the swelling that causes blurred vision in DME patients. If approved, it would be the first novel mechanism of action for retinal vascular diseases in more than 20 years — a milestone that has analysts and ophthalmologists paying close attention.
By the Numbers:
Why it matters: DME is a leading cause of vision loss in working-age adults, and current anti-VEGF therapies don't work for everyone. A new mechanism could expand treatment options — but safety concerns around higher discontinuation rates due to retinal vascular complications need to be fully characterized before remigromig can realize its clinical potential. Full results will be presented at the American Academy of Ophthalmology annual meeting next month.
